Nematode Infections: Clinical Trials

23 trials for Nematode Infections, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

19 completed, 2 recruiting, 2 terminated. 23 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 123Completed 19, Recruiting 2, Terminated 2
Phase 21Completed 1

Follow Nematode Infections: new trials by email Literature Review of Nematode Infections trials Research Report on Nematode Infections

Trials (filtered) newest first · largest first

All 23 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Controlled Human Infection Study of Orally Administered Trichuris Trichiura Eggs in Naïve Adults
Trichuris trichiura Egg Inoculum - Whipworm, Trichuriasis
Phase 1RecruitingGeorge Washington University182025-09-102026-06-04
Safety, Tolerability and PK of Single and Multiple Doses of Oxantel Pamoate Tablets
Oxantel Pamoate, Placebo - Healthy
Phase 1CompletedSwiss Tropical & Public Health Institute452025-01-272025-08-28
A Study to Learn About How Much Emodepside Gets Absorbed in the Blood and How Food Affects Its Absorption When Given as a New Type of Tablet to Healthy Participants
BAY 44-4400 - Soil-transmitted Helminth Infection, Onchocerciasis (River Blindness)
Phase 1CompletedBayer142024-05-072024-09-27
PK, Safety and Tolerability of Single and Multiple Doses of Oxfendazole Tablets
Oxfendazole, Placebo - Filariasis
Phase 1CompletedSwiss Tropical & Public Health Institute302022-04-212022-12-20
Development of AWZ1066S, a Small Molecule Anti-Wolbachia Candidate Macrofilaricide Drug
AWZ1066S, Placebo - Filariasis, Lymphatic, Onchocerciasis
Phase 1TerminatedLiverpool School of Tropical Medicine302021-12-102023-09-21
A Pharmacokinetic and Safety Study of Moxidectin to Identify an Optimal Dose for Treatment of Children 4 to 11 Years
Moxidectin - Onchocerciasis
Phase 1CompletedMedicines Development for Global Health362021-03-292025-09-05
Na-GST-1/Alhydrogel With or Without CpG 10104 in Gabonese Adults
Na-GST-1, CPG 10104 - Hookworm Infection, Hookworm Disease
Phase 1CompletedBaylor College of Medicine242018-02-012021-01-13
Safety, Tolerability and PK of Multiple-ascending Doses of Emodepside
LSF emodepside (BAY 44-4400) or matching placebo - Filariasis
Phase 1CompletedDrugs for Neglected Diseases242017-11-142020-04-15
Relative Bioavailability Study of Emodepside IR-tablets and Solution
Emodepside (BAY 44-4400) - Filariasis
Phase 1CompletedDrugs for Neglected Diseases772017-10-262020-03-09
Study of Co-administered Na-APR-1 (M74) and Na-GST-1 in Gabonese Children
Na-GST-1/Alhydrogel, Na-APR-1 (M74)/Alhydrogel, Hepatitis B Vaccine - Hookworm Disease, Hookworm Infection
Phase 1CompletedBaylor College of Medicine602017-01-012025-01-13
Pharmacokinetics & Pharmacodynamics of Diethylcarbamazine (DEC)+ Albendazole (ALB) + Ivermectin (IVE)
Ivermectin, Diethylcarbamazine Albendazole (IDA) - Wuchereria Bancrofti Infection
Phase 1CompletedUniversity Hospitals Cleveland Medical Center662016-04-172019-04-26
Study of Na-APR-1 (M74)/Alhydrogel® Co-administered With Na-GST-1/Alhydrogel in Brazilian Adults
Na-GST-1/Alhydrogel plus GLA-AF, Na-APR-1 (M74)/Alhydrogel, Na-APR-1 (M74)/Alhydrogel plus GLA-AF - Hookworm Infection, Hookworm Disease
Phase 1CompletedBaylor College of Medicine602016-01-012019-12-03
First in Man Clinical Trial of Emodepside (BAY 44-4400)
emodepside (BAY 44-4400), placebo - Healthy Volunteers
Phase 1CompletedDrugs for Neglected Diseases792015-12-012020-04-13
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
Necator americanus Hookworm Larvae - Hookworm Infection
Phase 1RecruitingBaylor College of Medicine352015-01-012026-05-18
Safety and Immunogenicity of Co-Administered Hookworm Vaccine Candidates Na-GST-1 and Na-APR-1 in Gabonese Adults
Na-APR-1 (M74)/Alhydrogel®, Na-GST-1/Alhydrogel®, Hepatitis B vaccine - Hookworm Infection, Hookworm Disease
Phase 1CompletedBaylor College of Medicine322014-11-012017-05-31
Safety and Immunogenicity Study of Na-GST-1 With or Without CpG
Na-GST-1/Alhydrogel®, CpG 10104 - Hookworm Infection, Hookworm Disease
Phase 1CompletedBaylor College of Medicine242014-10-012025-07-04
Safety and Immunogenicity of the Na-APR-1 Hookworm Vaccine in Healthy Adults
Na-APR-1 (M74)/Alhydrogel®, Gluco-Pyranosylphospho-Lipid A Aqueous Formulation - Hookworm Infection, Hookworm Disease
Phase 1CompletedBaylor College of Medicine402013-09-012019-07-31
Desensitising Celiac Disease Patients With the Human Hookworm
Necator americanus - Celiac Disease
Phase 1 / Phase 2CompletedThe Prince Charles Hospital122012-08-012014-10-20
Impact of Health Education on School Children
Health Education package - Intestinal Helminthiasis
Phase 1CompletedUniversity of Malaya3172012-07-012014-06-24
Safety and Immunogenicity of a Human Hookworm Candidate Vaccine With Different Doses of a Novel Adjuvant
10 μg Na-GST-1/Alhydrogel, 30 μg Na-GST-1/Alhydrogel, 100 μg Na-GST-1/Alhydrogel - Hookworm Infection, Hookworm Disease
Phase 1CompletedBaylor College of Medicine402012-05-012025-01-06

Showing 20 of 23. Sign in to see all of them.

Narrower conditions

Ancylostomiasis (12)  ·  Hookworm Infections (11)  ·  Neglected Diseases (7)  ·  Anemia, Iron-Deficiency (6)  ·  Onchocerciasis (5)  ·  Filariasis (4)  ·  Parasitic Diseases (3)  ·  Elephantiasis, Filarial (2)  ·  Trichuriasis (2)  ·  Celiac Disease (1)  ·  Health Education (1)  ·  Helminthiasis (1)  ·  Intestinal helminthiasis (1)  ·  Onchocerciasis, Ocular (1)

Broader conditions

Infections (23)  ·  Helminthiasis (22)  ·  Parasitic Diseases (20)  ·  Secernentea Infections (20)  ·  Strongylida Infections (13)  ·  Hemic and Lymphatic Diseases (8)  ·  Disease Attributes (7)  ·  Metabolic Diseases (7)  ·  Nutritional and Metabolic Diseases (7)  ·  Pathologic Processes (7)  ·  Pathological Conditions, Signs and Symptoms (7)  ·  Spirurida Infections (7)  ·  Anemia (6)  ·  Anemia, Hypochromic (6)

Interventions

Bay 44-4400 (4)  ·  Hepatitis B Vaccines (2)  ·  emodepside (2)  ·  ASP-1 protein, Necator americanus (1)  ·  CPG-oligonucleotide (1)  ·  D-Worm (1)  ·  GLA-AF adjuvant (1)  ·  Granuflex E (1)  ·  Ivermectin (1)  ·  Praziquantel (1)  ·  moxidectin (1)  ·  oxantel pamoate (1)  ·  oxfendazole (1)  ·  toltrazuril (1)

Sponsors

Baylor College of Medicine (10)  ·  Drugs for Neglected Diseases (3)  ·  Swiss Tropical & Public Health Institute (2)  ·  Albert B. Sabin Vaccine Institute (1)  ·  Bayer (1)  ·  George Washington University (1)  ·  Liverpool School of Tropical Medicine (1)  ·  Medicines Development for Global Health (1)  ·  The Prince Charles Hospital (1)  ·  University Hospitals Cleveland Medical Center (1)  ·  University of Malaya (1)

Countries

United States (6)  ·  United Kingdom (4)  ·  Brazil (3)  ·  Gabon (3)  ·  Tanzania (2)  ·  Australia (1)  ·  Côte d’Ivoire (1)  ·  Germany (1)  ·  Ghana (1)  ·  Malaysia (1)

Top investigators

David Diemert, MD (4)  ·  Ayola Adegnika, MD (3)  ·  David J Diemert, MD (3)  ·  Ahmed K. Al-Delaimy, MSc (1)  ·  Alexander Loukas, PhD (1)  ·  Daniel Paris (1)  ·  Daniel Paris, MD, PhD (1)  ·  Dianne Jones, BAppSc (1)  ·  Frederic Monnot (1)  ·  Gary Simon, M.D., Ph.D (1)  ·  Graham Devereux, MD (1)  ·  Hesham M Al-Mekhlafi, PhD (1)  ·  Hussein Mbarak, MD (1)  ·  Jennifer Keiser, PhD (1)  ·  Jeremy Dennison (1)

Results publications

PMID 28464026, PMID 18396361, PMID 22633322, PMID 29780848, PMID 31107869, PMID 32926834, PMID 34310218, PMID 34597297, PMID 37262040, PMID 38513684, PMID 38924387, PMID 40707999, PMID 41121745, PMID 41662151, PMID 41705834, PMID 42848323

NIH funding

2017 (2), 2015 (1), 2023 (1)